OBJECTIVES: To investigate the gene mutational profile of urachal carcinoma in correlation with its clinicopathologic features. METHODS: We analyzed genetic mutations in 30 cases of urachal carcinoma by next-generation sequencing (NGS) test. Histologic slides and clinical data were reviewed. RESULTS: The patients included 21 men and 9 women, with a mean age of 53 years (range, 24-75 years). The urachal carcinomas included mucinous (11), enteric (10), signet ring cell (8), and high-grade neuroendocrine (1) subtypes. Targeted NGS analysis demonstrated genetic mutations in all the urachal tumors (mean, 2; range, 1-4). TP53 was the most mutated gene (25), followed by KRAS (9) and GNAS (8) genes. TP53 mutations were more common in the signet ring cell subtype (7/8), and GNAS mutations were present only in the mucinous (5/11) and signet ring cell subtypes (3/8) but not in the enteric subtype (0/10). KRAS mutations were significantly associated with cancer stage IV (P = .02) and younger patient age (P = .046). Furthermore, the presence of KRAS mutations in urachal carcinoma portended a poorer overall survival (P = .006). CONCLUSIONS: Urachal carcinoma demonstrates frequent gene mutations that are associated with distinct clinicopathologic features. Gene mutation may underlie the development and progression of this aggressive disease.
OBJECTIVES: To investigate the gene mutational profile of urachal carcinoma in correlation with its clinicopathologic features. METHODS: We analyzed genetic mutations in 30 cases of urachal carcinoma by next-generation sequencing (NGS) test. Histologic slides and clinical data were reviewed. RESULTS: The patients included 21 men and 9 women, with a mean age of 53 years (range, 24-75 years). The urachal carcinomas included mucinous (11), enteric (10), signet ring cell (8), and high-grade neuroendocrine (1) subtypes. Targeted NGS analysis demonstrated genetic mutations in all the urachal tumors (mean, 2; range, 1-4). TP53 was the most mutated gene (25), followed by KRAS (9) and GNAS (8) genes. TP53 mutations were more common in the signet ring cell subtype (7/8), and GNAS mutations were present only in the mucinous (5/11) and signet ring cell subtypes (3/8) but not in the enteric subtype (0/10). KRAS mutations were significantly associated with cancer stage IV (P = .02) and younger patient age (P = .046). Furthermore, the presence of KRAS mutations in urachal carcinoma portended a poorer overall survival (P = .006). CONCLUSIONS: Urachal carcinoma demonstrates frequent gene mutations that are associated with distinct clinicopathologic features. Gene mutation may underlie the development and progression of this aggressive disease.
Authors: Gang Wang; He Huang; Ashish M Kamat; Arlene Siefker-Radtke; Colin P Dinney; Patricia Troncoso; Bogdan Czerniak; Charles C Guo Journal: Hum Pathol Date: 2017-08-18 Impact factor: 3.466
Authors: S A Ahrendt; P A Decker; E A Alawi; Y R Zhu Yr; M Sanchez-Cespedes; S C Yang; G B Haasler; A Kajdacsy-Balla; M J Demeure; D Sidransky Journal: Cancer Date: 2001-09-15 Impact factor: 6.860
Authors: Rajyalakshmi Luthra; Keyur P Patel; Mark J Routbort; Russell R Broaddus; Jonathan Yau; Crystal Simien; Wei Chen; David Z Hatfield; L Jeffrey Medeiros; Rajesh R Singh Journal: J Mol Diagn Date: 2016-12-23 Impact factor: 5.568
Authors: H Max Bruins; Otto Visser; Martine Ploeg; Christina A Hulsbergen-van de Kaa; Lambertus A L M Kiemeney; J Alfred Witjes Journal: J Urol Date: 2012-08-15 Impact factor: 7.450
Authors: R R Singh; K P Patel; M J Routbort; K Aldape; X Lu; J Manekia; R Abraham; N G Reddy; B A Barkoh; J Veliyathu; L J Medeiros; R Luthra Journal: Br J Cancer Date: 2014-10-14 Impact factor: 7.640
Authors: Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen Journal: Cancer Discov Date: 2019-10-28 Impact factor: 38.272